DigitalVision Systems

DVS Sciences, originally founded as Digital Vision Systems, was a transformative life sciences company that developed and commercialized the CyTOF (Cytometry by Time-Of-Flight) mass cytometry platform. This revolutionary technology combines the high-throughput capabilities of flow cytometry with the precision of mass spectrometry, allowing for the simultaneous measurement of over 40 cellular parameters at the single-cell level using metal-tagged antibodies. By overcoming the spectral overlap limitations of traditional fluorescence-based methods, the CyTOF platform provides unprecedented resolution of cellular heterogeneity and signaling pathways. The company was acquired by Fluidigm Corporation (now Standard BioTools) in 2014 for approximately $207 million, and its technology remains a cornerstone of high-parameter protein analysis in oncology and immunology research.